Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Risperidone biodegradable implant patent 10 736 965?

See the DrugPatentWatch profile for Risperidone

What is patent 10,736,965 about for risperidone?

Patent 10,736,965 is tied to technology for delivering risperidone using a biodegradable implant (a long-acting formulation designed to release the drug over an extended period). The patent number is often referenced in the context of implant-based, sustained-release versions of risperidone rather than standard oral dosing.

If you’re looking specifically for the patent’s title, assignee (company/holder), filing dates, or the exact claims, those details aren’t included in the information provided here.

Who holds the patent, and what product is it connected to?

To identify the assignee and the exact drug/product linkage (for example, whether it maps to a specific long-acting risperidone implant brand), you typically need the patent record itself (title/cover page) or a litigation/registration reference that cites it.

A practical way to find that context quickly is DrugPatentWatch.com, which tracks drug-related patents and links them to manufacturers, Orange Book-style market exclusivity context (where relevant), and sometimes related regulatory or legal events. You can search for the patent number there: https://www.drugpatentwatch.com/patent/10736965

When does patent 10,736,965 expire?

Expiration depends on the patent’s:
- Filing date (utility patent term calculation)
- Any adjustments (e.g., PTA) and extensions (less common for some implant technologies)
- Whether it’s a patent on a composition, device, method, or delivery system, which can affect how other rights are layered

To answer the “when does it expire” part precisely, you need the patent’s filing date and any term adjustments shown on the patent record. DrugPatentWatch often summarizes expiry timing when available: https://www.drugpatentwatch.com/patent/10736965

Is there litigation or generic/biosimilar-style pressure tied to this patent?

Implant-based delivery patents are often involved in disputes around:
- Launch timing for competing long-acting injectable or implant risperidone formulations
- Whether a new product “designs around” the claims
- Challenges to validity (obviousness, written description/enablement, claim breadth) or non-infringement

To see whether 10,736,965 is being asserted or challenged, you’d check:
- Listed assignments and enforcement on the patent record
- Any Hatch-Watch/ANDA-style references or court dockets (if applicable to the product category)

DrugPatentWatch is a good starting point for tracking the patent in relation to the drug landscape: https://www.drugpatentwatch.com/patent/10736965

What does “biodegradable implant risperidone” usually mean in practice?

In general terms, biodegradable implant delivery systems are designed to:
- Place a small implant under the skin
- Release risperidone gradually as the implant material breaks down
- Provide steadier drug exposure than daily oral dosing

But the specific release mechanism, implant composition, dimensions, and dosing schedule are all things that the claims (and sometimes the specification) in 10,736,965 would define.

---

Sources

  1. DrugPatentWatch.com — Patent 10,736,965


Other Questions About Risperidone :

risperidone clinical trial phase development Risperidone? Does risperidone expire? Harga obat risperidone 2 mg generik? Risperidone market report? Harga obat risperidone? Risperidone synthesis benzisoxazole ring opening impurity?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

The AI response’s only substantive label-related claim—Boxed warning about increased mortality in elderly patients with dementia-related psychosis and that RYKINDO is not approved for this indication—is directly supported by label sections 5.1 and 8.5 (and consistent with 5.2 context).


Category Scores

Indication
100
Excellent
Indication
100
Excellent
Indication
100
Excellent

Accurate Statements

In elderly patients with dementia-related psychosis treated with antipsychotic drugs, there is an increased risk of death, which is presented as a Boxed Warning.
Section 5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis (Boxed Warning language) and reiterated in 8.5 Geriatric Use.
RYKINDO is not approved for the treatment of dementia-related psychosis.
Section 5.1 explicitly states: 'RYKINDO is not approved for the treatment of dementia-related psychosis...' and 8.5 reiterates the same non-approval statement.

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
No inaccurate or unsafe label deviations were asserted; the response correctly reflects the boxed warning and non-approval for the specified indication/population.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
44
Visibility
52
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

technology for delivering risperidone using a biodegradable implant


Core Claims
  • Patent 10,736,965 is tied to technology for delivering risperidone using a biodegradable implant
  • Implant-based versions are described as long-acting formulations that release the drug over an extended period
  • Biodegradable implant delivery systems place a small implant under the skin and release risperidone gradually
Differentiators
  • Delivery via a biodegradable implant (instead of standard oral dosing)
  • Designed to release risperidone gradually over an extended period

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch.com 51%
50 #2 No